GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ANIP · Jun 30, 2021

ANI PHARMACEUTICALS INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001023024-21-000017General Corporate
Debt relative to revenue100thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.debt_to_revenue

420.99% · OPTIONAL · VALID

Capex intensity10thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

1.92% · OPTIONAL · VALID

Operating cash generation10thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

0.50% · OPTIONAL · VALID

Revenue growth10thOwn-history percentile · N=20
Evidence method

Yoy · gp.fundamentals.revenue

0.32% · CORE · VALID

Inventory pressure100thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

139.09% · OPTIONAL · VALID

Operating margin0thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.operating_margin

-31.99% · CORE · VALID

R&D intensity50thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

5.77% · OPTIONAL · VALID

SBC intensity85thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

5.85% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History49 statesSelf-history eligible
Sep 30, 20218/8 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Mar 31, 20228/8 normalizedLevel 3Jun 30, 20228/8 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 4
Period transition

What moved in the state?

Balance Sheet Leverage Increased
Previous
336.43%
Current
420.99%
Delta
84.56%
Capex Intensity Increased
Previous
1.28%
Current
1.92%
Delta
0.64%
Cash Generation Decreased
Previous
37.91%
Current
0.50%
Delta
-37.41%
Growth Decreased
Previous
9.54%
Current
0.32%
Delta
-9.22%
Inventory Pressure Increased
Previous
109.92%
Current
139.09%
Delta
29.18%
Profitability Decreased
Previous
5.58%
Current
-31.99%
Delta
-37.57%
R And D Intensity Increased
Previous
5.44%
Current
5.77%
Delta
0.32%
Sbc Intensity Increased
Previous
3.43%
Current
5.85%
Delta
2.42%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · ANIP Fundamental State →Transitioned To · ANIP Fundamental State →Transitioned To · ANIP BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · ANIP CAPEX_INTENSITY_INCREASED →Transitioned To · ANIP CASH_GENERATION_DECREASED →Transitioned To · ANIP GROWTH_DECREASED →Transitioned To · ANIP INVENTORY_PRESSURE_INCREASED →Transitioned To · ANIP PROFITABILITY_DECREASED →Transitioned To · ANIP R_AND_D_INTENSITY_INCREASED →Transitioned To · ANIP SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.